Frontal Fibrosing Alopecia: Study Finds Oral Contraceptive Use Modulates Risk In Women with Genetic Variant

<?xml version="1.0" encoding="UTF-8"?>
<!--$RCSfile: InCopy_agile.xsl,v $ $Revision: 1.35 $-->
<!--$RCSfile: drupal.xsl,v $ $Revision: 1.7 $-->
<root generator="drupal.xsl" gversion="1.7"> <header> <fileName>168277</fileName> <TBEID>0C050625.SIG</TBEID> <TBUniqueIdentifier>MD_0C050625</TBUniqueIdentifier> <newsOrJournal>News</newsOrJournal> <publisherName>Frontline Medical Communications</publisherName> <storyname/> <articleType>2</articleType> <TBLocation>QC Done-All Pubs</TBLocation> <QCDate>20240603T120906</QCDate> <firstPublished>20240603T123128</firstPublished> <LastPublished>20240603T123128</LastPublished> <pubStatus qcode="stat:"/> <embargoDate/> <killDate/> <CMSDate>20240603T123128</CMSDate> <articleSource/> <facebookInfo/> <meetingNumber/> <byline>AI</byline> <bylineText>EDITED ELIZABETH MECHCATIE</bylineText> <bylineFull>EDITED ELIZABETH MECHCATIE</bylineFull> <bylineTitleText/> <USOrGlobal/> <wireDocType/> <newsDocType>News</newsDocType> <journalDocType/> <linkLabel/> <pageRange/> <citation/> <quizID/> <indexIssueDate/> <itemClass qcode="ninat:text"/> <provider qcode="provider:imng"> <name>IMNG Medical Media</name> <rightsInfo> <copyrightHolder> <name>Frontline Medical News</name> </copyrightHolder> <copyrightNotice>Copyright (c) 2015 Frontline Medical News, a Frontline Medical Communications Inc. company. All rights reserved. This material may not be published, broadcast, copied, or otherwise reproduced or distributed without the prior written permission of Frontline Medical Communications Inc.</copyrightNotice> </rightsInfo> </provider> <abstract/> <metaDescription>the use of oral contraceptives (OCs) may be associated with an increased risk for frontal fibrosing alopecia (FFA) in women with a common variant in the CYP1B1 </metaDescription> <articlePDF/> <teaserImage/> <teaser>The study suggests a significant gene-environment interaction, the authors wrote.</teaser> <title>Frontal Fibrosing Alopecia: Study Finds Oral Contraceptive Use Modulates Risk In Women with Genetic Variant</title> <deck/> <disclaimer/> <AuthorList/> <articleURL/> <doi/> <pubMedID/> <publishXMLStatus/> <publishXMLVersion>1</publishXMLVersion> <useEISSN>0</useEISSN> <urgency/> <pubPubdateYear/> <pubPubdateMonth/> <pubPubdateDay/> <pubVolume/> <pubNumber/> <wireChannels/> <primaryCMSID/> <CMSIDs/> <keywords/> <seeAlsos/> <publications_g> <publicationData> <publicationCode>skin</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>endo</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>fp</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>im</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> <publicationData> <publicationCode>ob</publicationCode> <pubIssueName/> <pubArticleType/> <pubTopics/> <pubCategories/> <pubSections/> </publicationData> </publications_g> <publications> <term canonical="true">13</term> <term>34</term> <term>15</term> <term>21</term> <term>23</term> </publications> <sections> <term>27970</term> <term canonical="true">39313</term> </sections> <topics> <term canonical="true">219</term> <term>287</term> <term>203</term> <term>322</term> <term>200</term> </topics> <links/> </header> <itemSet> <newsItem> <itemMeta> <itemRole>Main</itemRole> <itemClass>text</itemClass> <title>Frontal Fibrosing Alopecia: Study Finds Oral Contraceptive Use Modulates Risk In Women with Genetic Variant</title> <deck/> </itemMeta> <itemContent> <h2>TOPLINE:</h2> <p>Investigators found that <span class="tag metaDescription">the use of oral contraceptives (OCs) may be associated with an increased risk for frontal fibrosing alopecia (FFA) in women with a common variant in the <em>CYP1B1</em> gene</span>.</p> <h2>METHODOLOGY:</h2> <ul class="body"> <li>OC use has been considered a possible factor behind the increased incidence of FFA because it was first documented in 1994, and a recent genome-wide association study of FFA identified a signal for an association with a variant in <em>CYP1B1</em>.</li> <li>The same researchers conducted a gene-environment interaction study with a case-control design involving 489 White female patients (mean age, 65.8 years) with FFA and 34,254 controls, matched for age and genetic ancestry.</li> <li>Data were collected from July 2015 to September 2017 and analyzed from October 2022 to December 2023.</li> <li>The study aimed to investigate the modulatory effect of OC use on the <em>CYP1B1</em> variant’s impact on FFA risk, using logistic regression models for analysis.</li> </ul> <h2>TAKEAWAY:</h2> <ul class="body"> <li>The use of OCs was associated with a 1.9 times greater risk for FFA in individuals with the specific CYP1B1 genetic variant, but there was no association among those with no history of OC use.</li> <li>The study suggests a significant gene-environment interaction, indicating that OC use may influence FFA risk in genetically predisposed individuals.</li> </ul> <h2>IN PRACTICE:</h2> <p>“This gene-environment interaction analysis suggests that the protective effect of the <em>CYPIB</em>1 missense variant on FFA risk might be mediated by exposure” to OCs, the authors wrote. The study, they added, “underscores the importance of considering genetic predispositions and environmental factors, such as oral contraceptive use, in understanding and managing frontal fibrosing alopecia.”</p> <h2>SOURCE:</h2> <p>Tuntas Rayinda, MD, MSc, PhD, of St. John’s Institute of Dermatology, King’s College London, led the study, which was <a href="https://jamanetwork.com/journals/jamadermatology/article-abstract/2819419">published online</a> May 29, 2024, in <em>JAMA Dermatology</em>.</p> <h2>LIMITATIONS:</h2> <p>The study’s reliance on self-reported OC use may have introduced recall and differences in ascertainment of OC use between patient and control groups and could have affected the study’s findings. The study also did not collect information on the type of OC used, which could have influenced the observed interaction.</p> <h2>DISCLOSURES:</h2> <p>The study was supported by the British Skin Foundation Young Investigator Award. One investigator reported being a subinvestigator on an alopecia areata study funded by Pfizer. No other disclosures were reported.</p> <p>This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication. </p> <p> <em>A version of this article appeared on <span class="Hyperlink"><a href="https://www.medscape.com/viewarticle/oral-contraceptives-may-play-role-risk-frontal-fibrosing-2024a1000acd">Medscape.com</a></span>.</em> </p> </itemContent> </newsItem> <newsItem> <itemMeta> <itemRole>teaser</itemRole> <itemClass>text</itemClass> <title/> <deck/> </itemMeta> <itemContent> </itemContent> </newsItem> </itemSet></root>